2 not yet recruiting, 2 recruiting. 2 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Not yet recruiting 1, Recruiting 1 |
| Not applicable | 1 | Recruiting 1 |
Follow Ji Yongling: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase I Study of Carbon-Ion Lattice Radiotherapy for Large Thoracic Tumors Carbon ion - Lattice radioIon Lattice Radiation Therapy for Thoracic bulky solid tumors - Carbon Ion Radiotheray | Not applicable | Recruiting | Ji Yongling | 12 | 2026-05-26 | 2026-08-04 |
| Neoadjuvant Chemoimmunotherapy or Chemoradiotherapy in ESCC Neoadjuvant Chemoimmunotherapy or Concurrent Chemoradiotherapy - Resectable Esophageal Cancer | Phase 2 | Not yet recruiting | Ji Yongling | 66 | 2026-01-28 | 2026-02-04 |
| Efficacy and Safety of Chemoimmunotherapy and Carbon Ion Radiotherapy in Unresectable Locally Advanced Non-small Cell Lung Cancer Carbon ion radiotherapy, Chemotherapy, Immunotherapy - Carbon Ion Radiotheray | Not yet recruiting | Ji Yongling | 34 | 2025-06-16 | 2025-06-25 | |
| Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC Anlotinib Hydrochloride Capsule, Tislelizumab Injection, Hypofractionated Radiotherapy - Non-Small Cell Lung Cancer | Phase 2 | Recruiting | Ji Yongling | 20 | 2024-05-01 | 2025-07-10 |
Carcinoma, Non-Small-Cell Lung (2)
Chemoradiotherapy (1) · Drug Therapy (1) · Heavy Ion Radiotherapy (1) · Immunotherapy (1) · Radiation Dose Hypofractionation (1) · anlotinib (1) · tislelizumab (1)
China (4)
YongLing Ji, PhD (1) · Yongling JI, MD (1) · Yongling Ji, MD (1)